Immunome (IMNM) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

Immunome Revenue Highlights


Latest Revenue (Y)

$14.02M

Latest Revenue (Q)

$2.36M

Immunome Revenue by Period


Immunome Revenue by Year

DateRevenueChange
2023-12-31$14.02M100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31--

Immunome generated $14.02M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Immunome Revenue by Quarter

DateRevenueChange
2024-06-30$2.36M129.74%
2024-03-31$1.03M-73.11%
2023-12-31$3.83M7.32%
2023-09-30$3.56M-16.37%
2023-06-30$4.26M80.33%
2023-03-31$2.36M100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--

Immunome generated $2.36M in revenue during Q2 2024, up 129.74% compared to the previous quarter, and up 100.00% compared to the same period a year ago.

Immunome Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
ADAGAdagene$18.11M$833.34K
ANABAnaptysBio$17.16M$10.97M
IMNMImmunome$14.02M$2.36M
IKNAIkena Oncology$9.16M-
MOLNMolecular Partners$7.04M$2.74M
MNOVMediciNova$1.00M-
TFFPTFF Pharmaceuticals$733.87K$650.22K
LIFEaTyr Pharma$353.00K$235.00K
GANXGain Therapeutics$55.18K-
ANEBAnebulo Pharmaceuticals--
RZLTRezolute--
ANTXAN2 Therapeutics--
AVTEAerovate Therapeutics--
INABIN8bio--
CYTCyteir Therapeutics--
ACRVAcrivon Therapeutics--
CELCCelcuity--
MLYSMineralys Therapeutics--
LTRNLantern Pharma--
CSBRChampions Oncology--

IMNM Revenue FAQ


Immunome's yearly revenue for 2023 was $14.02M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. IMNM's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.

Immunome's quarterly revenue for Q2 2024 was $2.36M, a 129.74% increase from the previous quarter (Q1 2024), and a -44.55% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.03M, a -73.11% decrease from the previous quarter (Q4 2023), and a -56.47% decrease year-over-year (Q1 2023). IMNM's quarterly revenue for Q4 2023 was $3.83M, a 7.32% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).

Immunome's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.